New transdermal patch

An easier way to administer an established treatment for Alzheimer’s disease has been developed by Luye Pharma.  The twice weekly Zeyzelf rivastigmine transdermal patch is said by the company to be simpler than the daily rivastigmine patches already in circulation.  It is also 52% less expensive than some other patches, the company says.

Rivastigmine reduce symptoms of mild to moderate Alzhemer’s and the patches are a useful alternative where people are unwilling to unable to swallow tablets.  “We know that transdermal delivery can be advantageous to both patients and carers and by having a patch that only has to be applied twice a week, rather than daily, will significantly reduce the carer burden and also potentially improve compliance,” said Luye Pharma general manager Andy Farrant.